You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國生物科技服務(08037.HK)聯手安盛、前海再保險等四方合作 開發BNCT普惠型醫療保險

格隆匯7月11日丨中國生物科技服務(08037.HK)發佈公告,2025年7月10日,公司、安盛保險(百慕達)有限公司(“AXA安盛香港”,於百慕達註冊成立的有限公司)及安盛環球再保險(上海)有限公司(“安盛環球再保險”,連同AXA安盛香港,統稱“AXA安盛”)、前海再保險股份有限公司(“前海再保險”)及Arthur J. Gallagher (Singapore) Pte. Ltd.(“安睿嘉爾”)訂立一份不具法律約束力的諒解備忘錄,內容有關共同開發覆蓋硼中子治療(BNCT)治療費用及相關服務的普惠型醫療保險產品的合作。

公告表示,與領先的保險╱再保險公司和再保險經紀人進行四方合作,旨在開發覆蓋BNCT 治療費用及相關服務的普惠型醫療保險產品,以降低患者經濟負擔,提升治療可及性。憑藉集團在BNCT市場的領導地位和合作夥伴的廣泛網絡,該合作將爲集團的BNCT業務帶來協同效應,爲更多中國及海外患者提供BNCT治療。這突顯了集團長期以來致力推動BNCT治療和改善全球患者治療效果的承諾。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account